Company profile
Gemina Laboratories Ltd.
OTC: GLABF · Healthcare · Biotechnology
Canadian filerHQ Burnaby, BCReports USD
#1119 of 1,418 Healthcare companies by revenue
EA Score
——FH 25DQ —GM —SS 24
v0.1 · 35/100 weight · pillars only
↑ Piotroski F, disclosure history · ↓ operating margin, net margin
Methodology →Revenue TTM
$15.3k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.7M
Employees
6
as of 2026-08-24
Market cap
$3.8M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$15.4k21.5k CAD2025
Net income-$1.7M-2.3M CAD2025
Operating income-$1.6M-2.2M CAD2025
Total assets$1.2M1.6M CAD2025
Liabilities$5.6M7.6M CAD2025
Equity-$4.4M-6.0M CAD2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Gemina Laboratories Ltd.’s revenue?
Gemina Laboratories Ltd. booked $15.4k in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -10893.2% net margin.
Peers · Healthcare
Sector 10, Inc.——Nanobac Pharmaceuticals, Incorporated——REMSleep Holdings, Inc.19DUpper Street Marketing Inc.——Pineapple, Inc.——Cardio Diagnostics Holdings, Inc.30DKey facts
CEORobert Crandall Greene
SectorHealthcare
IndustryBiotechnology
HeadquartersBurnaby, BC
ExchangeOTC: GLABF
Employees6
IPO date2022-03-29
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.